IGM Biosciences (IGMS) investor relations material

Executive summary

• Entered into a Merger Agreement with Concentra Biosciences, with closing expected in August 2025, subject to conditions including minimum net cash and shareholder tender.

• Terminated all product development activities and closed all lab and office facilities following major restructurings in January and April 2025.

• Sanofi collaboration agreement was fully terminated in June 2025, resulting in recognition of all remaining deferred revenue.

• No current product candidates in development; future activities depend on outcome of the Merger.

Financial highlights

• Net income of $97.6 million for Q2 2025, compared to a net loss of $47.9 million in Q2 2024, driven by non-cash revenue from Sanofi agreement termination.

• Collaboration revenue of $143.6 million in Q2 2025, up from $1.3 million in Q2 2024, due to full recognition of deferred revenue.

• Research and development expenses decreased to $5.9 million in Q2 2025 from $42.0 million in Q2 2024, reflecting program wind-downs and workforce reductions.

• Impairment and disposal of long-lived assets charges of $31.9 million in Q2 2025, related to lease terminations and asset disposals.

• Cash, cash equivalents, and marketable securities totaled $104.3 million as of June 30, 2025.

Outlook and guidance

• Expenses and operating losses expected to decrease following restructuring and Sanofi agreement termination.

• If the Merger is not completed, the board may pursue dissolution or liquidation.

• No plans to develop new product candidates unless the Merger is not completed and a new strategy is adopted.